Synonym
GNF6702; GNF-6702; GNF 6702;
IUPAC/Chemical Name
N-{4-fluoro-3-[6-(pyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl}-2,4-dimethyl-1,3-oxazole-5-carboxamide
InChi Key
WXZFCGRYVWYYTG-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H16FN7O2/c1-12-19(32-13(2)26-12)21(31)27-15-6-7-17(23)16(9-15)20-28-22-25-10-14(11-30(22)29-20)18-5-3-4-8-24-18/h3-11H,1-2H3,(H,27,31)
SMILES Code
O=C(C1=C(C)N=C(C)O1)NC2=CC=C(F)C(C3=NN4C=C(C5=NC=CC=C5)C=NC4=N3)=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
429.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Smedley CJ, Barrow AS, Spiteri C, Giel MC, Sharma P, Moses JE. Sulfur-Fluoride
Exchange (SuFEx)-Mediated Synthesis of Sterically Hindered and Electron-Deficient
Secondary and Tertiary Amides via Acyl Fluoride Intermediates. Chemistry. 2017
Jul 26;23(42):9990-9995. doi: 10.1002/chem.201701552. PubMed PMID: 28612408.
2: Khare S, Nagle AS, Biggart A, Lai YH, Liang F, Davis LC, Barnes SW, Mathison
CJ, Myburgh E, Gao MY, Gillespie JR, Liu X, Tan JL, Stinson M, Rivera IC, Ballard
J, Yeh V, Groessl T, Federe G, Koh HX, Venable JD, Bursulaya B, Shapiro M, Mishra
PK, Spraggon G, Brock A, Mottram JC, Buckner FS, Rao SP, Wen BG, Walker JR,
Tuntland T, Molteni V, Glynne RJ, Supek F. Proteasome inhibition for treatment of
leishmaniasis, Chagas disease and sleeping sickness. Nature. 2016 Sep
8;537(7619):229-233. doi: 10.1038/nature19339. Epub 2016 Aug 8. PubMed PMID:
27501246; PubMed Central PMCID: PMC5161665.
